Hutchmed (china) Limited (HCM) RNS Announcements

Date	Time	Date	TitleTitle (filtered)
29/09/21	07:00:10	29 Sept 2021	HUTCHMED Highlights Presentations at CSCO 2021	HUTCHMED Highlights Presentations at CSCO 2021
21/09/21	07:00:10	21 Sept 2021	HUTCHMED Initiates Phase III Trial SURTORI-01	HUTCHMED Initiates Phase III Trial SURTORI-01
20/09/21	07:00:09	20 Sept 2021	Japan Bridging Study For Surufatinib Initiated	Japan Bridging Study For Surufatinib Initiated
13/09/21	07:00:08	13 Sept 2021	Breakthrough Therapy Designation for Amdizalisib	Breakthrough Therapy Designation for Amdizalisib
08/09/21	11:30:00	8 Sept 2021	HUTCHMED and AZ Initiate Phase III Trial in China	HUTCHMED and AZ Initiate Phase III Trial in China
07/09/21	09:30:08	7 Sept 2021	HUTCHMED to Present Clinical Data at ESMO	HUTCHMED to Present Clinical Data at ESMO
06/09/21	07:00:08	6 Sept 2021	HUTCHMED Shares Included in Stock Connect Programs	HUTCHMED Shares Included in Stock Connect Programs
02/09/21	12:45:06	2 Sept 2021	Grant of Share Options, and Awards under LTIP	Grant of Share Options, and Awards under LTIP
31/08/21	09:30:01	31 Aug 2021	Total Voting Rights	Total Voting Rights
26/08/21	07:00:03	26 Aug 2021	Phase Ib/II Trial of Fruquintinib & Tislelizumab	Phase Ib/II Trial of Fruquintinib & Tislelizumab
23/08/21	07:00:06	23 Aug 2021	HUTCHMED Selected for Certain Hang Seng Indexes	HUTCHMED Selected for Certain Hang Seng Indexes
17/08/21	09:30:03	17 Aug 2021	ELECTRONIC COMMUNICATION OF CORPORATE INFORMATION	ELECTRONIC COMMUNICATION OF CORPORATE INFORMATION

Showing 251–262 of 262 announcements

Hutchmed (china) Limited RNS